Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 and ED95 of ciprofol for anesthesia induction in morbidly obese patients
ChiCTR2400094305Phase 4Completed
- Sponsor
- Lishui People's Hospital
- Start
- Dec 2024
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ciprofol in class III obesity, sponsored by Lishui People's Hospital. Primary endpoints: ED50 for loss of consciousness with ciprofol and ED95 for loss of consciousness with ciprofol. Started Dec 2024; status: completed.
02
Drugs
ciprofol
03
Conditions
class III obesity
Beyond the preview
Go deeper on ChiCTR2400094305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094305.